Deutsch English Français

Contact

EP0872245

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP0872245

EP0872245 - Methods for treating vascular disorders with activated Protein C [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 12.01.2007 Database last updated on 20.12.2024
Most recent event Tooltip	01.08.2008	Lapse of the patent in a contracting state New state(s): LU	published on 03.09.2008 [2008/36]
Applicant(s)	For all designated states ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, IN 46285 / US
	[N/P]
Former [2006/10]	For all designated states ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis IN 46285 / US
Former [1998/43]	For all designated states ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, Indiana 46285 / US
Inventor(s)	01 / Grinnell, Brian William 3625 East 71st Street Indianapolis, Indiana 46220 / US
	02 / Howey, Daniel Charles 4524 Lakeridge Drive Indianapolis, Indiana 46234 / US
	03 / Van Jackson, Charles 99921 Leeward Boulevard Indianapolis, Indiana 46256 / US
	[1998/43]
Representative(s)	Kent, Lindsey Ruth, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB
	[N/P]
Former [2004/48]	Kent, Lindsey Ruth, et al Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road Windlesham, Surrey GU20 6PH / GB
Former [2001/29]	Denholm, Anna Marie, et al Eli Lilly and Company Limited, Lilli Research Centre, Erl Wood Manor Windlesham Surrey GU20 6PH / GB
Former [1998/43]	Hudson, Christopher Mark, et al Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor Windlesham Surrey GU20 6PH / GB
Application number, filing date	98302165.0	24.03.1998
	[1998/43]
Priority number, date	US19970042533P	24.03.1997 Original published format: US 42533 P
	US19970062549P	20.10.1997 Original published format: US 62549 P
	US19970064765P	07.11.1997 Original published format: US 64765 P
	[1998/43]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP0872245
	Date:	21.10.1998
	Language:	EN
	[1998/43]
	Type:	B1 Patent specification
	No.:	EP0872245
	Date:	08.03.2006
	Language:	EN
	[2006/10]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	14.07.1998
Classification	IPC:	A61K38/48, A61P7/02	[2005/36]
	CPC:	C12N9/6464 (EP); A61K38/00 (EP,KR); A61P43/00 (EP); A61P7/02 (EP); A61P9/00 (EP); A61P9/10 (EP); (+) C12Y304/21069 (EP) (-)
	Former IPC [1998/43]	A61K38/48, // C12N9/64
Designated contracting states	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE [1999/26]
Former [1998/43]	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
Extension states	AL	03.04.1998
	LT	03.04.1998
	LV	03.04.1998
	MK	03.04.1998
	RO	03.04.1998
	SI	03.04.1998
Title	German:	Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C	[1998/43]
	English:	Methods for treating vascular disorders with activated Protein C	[1998/43]
	French:	Procédé de traitement des maladies vasculaires avec la Protéine C activée	[1998/43]
Examination procedure	03.04.1998	Examination requested [1998/43]
	14.07.2003	Despatch of a communication from the examining division (Time limit: M06)
	16.01.2004	Reply to a communication from the examining division
	04.02.2004	Despatch of a communication from the examining division (Time limit: M06)
	03.06.2004	Reply to a communication from the examining division
	01.07.2004	Despatch of a communication from the examining division (Time limit: M05)
	13.12.2004	Reply to a communication from the examining division
	10.05.2005	Despatch of a communication from the examining division (Time limit: M02)
	14.07.2005	Reply to a communication from the examining division
	31.08.2005	Communication of intention to grant the patent
	15.12.2005	Fee for grant paid
	15.12.2005	Fee for publishing/printing paid
Opposition(s)	11.12.2006	No opposition filed within time limit [2007/07]
Fees paid	Renewal fee
	06.03.2000	Renewal fee patent year 03
	05.03.2001	Renewal fee patent year 04
	04.03.2002	Renewal fee patent year 05
	05.03.2003	Renewal fee patent year 06
	04.03.2004	Renewal fee patent year 07
	04.03.2005	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	08.03.2006
	BE	08.03.2006
	CH	08.03.2006
	FI	08.03.2006
	LI	08.03.2006
	NL	08.03.2006
	IE	24.03.2006
	LU	24.03.2006
	DK	08.06.2006
	SE	08.06.2006
	GR	09.06.2006
	PT	08.08.2006
	[2008/36]
Former [2008/21]	AT	08.03.2006
	BE	08.03.2006
	CH	08.03.2006
	FI	08.03.2006
	LI	08.03.2006
	NL	08.03.2006
	IE	24.03.2006
	DK	08.06.2006
	SE	08.06.2006
	GR	09.06.2006
	PT	08.08.2006
Former [2007/17]	AT	08.03.2006
	BE	08.03.2006
	CH	08.03.2006
	FI	08.03.2006
	LI	08.03.2006
	NL	08.03.2006
	IE	24.03.2006
	DK	08.06.2006
	SE	08.06.2006
	PT	08.08.2006
Former [2006/45]	AT	08.03.2006
	CH	08.03.2006
	FI	08.03.2006
	LI	08.03.2006
	NL	08.03.2006
	SE	08.06.2006
Former [2006/43]	AT	08.03.2006
	CH	08.03.2006
	FI	08.03.2006
	LI	08.03.2006
Former [2006/42]	CH	08.03.2006
	FI	08.03.2006
	LI	08.03.2006
Former [2006/36]	FI	08.03.2006
Documents cited:	Search	[X]EP0357296 (WELLCOME FOUND [GB]) [X] 1-8 whole document, especially page 4 line 55-page 5 line 10;
		[XD]US5084274 (GRIFFIN JOHN H [US], et al) [XD] 5-8* the whole document *;
		[X]EP0726076 (CHEMO SERO THERAPEUT RES INST [JP], et al) [X] 5-8 * the whole document *;
		[X] - OKAJIMA K. ET AL, "Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects", THROMBOSIS AND HAEMOSTASIS, (1990), vol. 63, no. 1, pages 48 - 53, XP000573858 [X] 1-8 * page 49, column 1, paragraph 4 * * page 51, column 2, paragraph 1 * * page 52, column 1, paragraph 2 *
		[X] - PYZH M V ET AL, "Effects of low doses of activated protein C in experimental arterial thrombosis in rats", MEDLINE, XP002069505 [X] 1-8 * abstract *
		[ ] - KARDIOLOGIIA (1990 AUG) 30 (8) 74-77

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p